HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leela Barham

Set Alert for Articles By Leela Barham

Latest From Leela Barham

Concerns Emerge Over England’s Desire For Even Lower Drug Prices

With the emphasis on getting lower prices even for cost-effective drugs, England’s proposed commercial framework may be sending a negative signal to global companies.

Pricing Strategies United Kingdom

We Need To Talk – When To Get Early Scientific Advice

Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.

BioPharmaceutical Europe

Fair Pricing A Key Feature Of NHS England Drug Funding Proposals

Plans for a new commercial framework for publicly funded medicines in England are out for consultation. The concept of fair and responsible pricing figures large in the proposals.

Pricing Debate United Kingdom

Metrics For Measuring UK Pricing Scheme Success: Good Start But More Work Needed

The Pink Sheet’s freedom of information request relating to the 2019 pricing and access to branded medicines scheme has shed light on the metrics being used to gauge whether the scheme is delivering on its promise.

United Kingdom Europe

Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.

Pricing Strategies Europe

Payment For Outcomes Key To EU Market Access for Yescarta

Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.

Europe France
See All
UsernamePublicRestriction

Register